Literature DB >> 17590448

The GABAA receptor: a novel target for treatment of fragile X?

Charlotte D'Hulst1, R Frank Kooy.   

Abstract

GABA(A) receptors are the major inhibitory neurotransmitter receptors in the mammalian brain, implicated in anxiety, depression, epilepsy, insomnia, and learning and memory. Here, we present several lines of evidence for involvement of the GABAergic system, and in particular the GABA(A) receptor-mediated function, in fragile X syndrome, the most common form of inherited mental retardation. We argue that an altered expression of the GABA(A) receptor has neurophysiologic and functional consequences that might relate to the behavioural and neurological phenotype associated with fragile X syndrome. Interestingly, some neuropsychiatric disorders, such as anxiety, epilepsy and sleep disorders, are effectively treated with therapeutic agents that act on the GABA(A) receptor. Therefore, the GABA(A) receptor might be a novel therapeutic target for fragile X syndrome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17590448     DOI: 10.1016/j.tins.2007.06.003

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  76 in total

1.  Disrupted GABAAR trafficking and synaptic inhibition in a mouse model of Huntington's disease.

Authors:  Eunice Y Yuen; Jing Wei; Ping Zhong; Zhen Yan
Journal:  Neurobiol Dis       Date:  2012-02-28       Impact factor: 5.996

Review 2.  Potential therapeutic interventions for fragile X syndrome.

Authors:  Josien Levenga; Femke M S de Vrij; Ben A Oostra; Rob Willemsen
Journal:  Trends Mol Med       Date:  2010-09-21       Impact factor: 11.951

Review 3.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

4.  The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.

Authors:  Jose Luis Olmos-Serrano; Joshua G Corbin; Mark P Burns
Journal:  Dev Neurosci       Date:  2011-11-08       Impact factor: 2.984

5.  Fragile X mental retardation protein in the driver's seat.

Authors:  Jay E Brenman
Journal:  Cereb Cortex       Date:  2009-04-22       Impact factor: 5.357

Review 6.  The state of synapses in fragile X syndrome.

Authors:  Brad E Pfeiffer; Kimberly M Huber
Journal:  Neuroscientist       Date:  2009-03-26       Impact factor: 7.519

Review 7.  GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition.

Authors:  Tija C Jacob; Stephen J Moss; Rachel Jurd
Journal:  Nat Rev Neurosci       Date:  2008-05       Impact factor: 34.870

8.  Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.

Authors:  Craig A Erickson; Logan K Wink; Balmiki Ray; Maureen C Early; Elizabeth Stiegelmeyer; Lauren Mathieu-Frasier; Vanessa Patrick; Debomoy K Lahiri; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2013-02-24       Impact factor: 4.530

9.  Inactivation of the maternal fragile X gene results in sensitization of GABAB receptor function in the offspring.

Authors:  Bojana Zupan; Miklos Toth
Journal:  J Pharmacol Exp Ther       Date:  2008-09-23       Impact factor: 4.030

Review 10.  Fragile X: a family of disorders.

Authors:  Weerasak Chonchaiya; Andrea Schneider; Randi J Hagerman
Journal:  Adv Pediatr       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.